{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:39:19Z","timestamp":1793479159397,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available pharmacologic options for the treatment of sleepiness in this population are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a double-blind, randomized, placebo-controlled, parallel-group, 12-week trial comparing solriamfetol, 37.5, 75, 150, and 300 mg, with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Of 476 randomized participants, 459 were included in the prespecified efficacy analyses. Coprimary endpoints (Maintenance of Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol doses (P\u2009&amp;lt;\u20090.05), with dose-dependent effects observed at Week 1 maintained over the study duration. All doses except 37.5 mg resulted in higher percentages of participants reporting improvement on Patient Global Impression of Change (key secondary endpoint; P\u2009&amp;lt;\u20090.05). Adverse events were reported in 47.9% of placebo- and 67.9% of solriamfetol-treated participants; five participants experienced serious adverse events (two [1.7%] placebo, three [0.8%] solriamfetol); none were deemed related to study drug. The most common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in severity.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT02348606) and www.eudract.ema.europa.eu (EudraCT 2014-005514-31).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201806-1100oc","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T17:45:01Z","timestamp":1544118301000},"page":"1421-1431","source":"Crossref","is-referenced-by-count":155,"title":["Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial"],"prefix":"10.1093","volume":"199","author":[{"given":"Paula K.","family":"Schweitzer","sequence":"first","affiliation":[{"name":"Sleep Medicine and Research Center, St. Luke\u2019s Hospital, Chesterfield, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"NeuroTrials Research, Atlanta, Georgia"},{"name":"Atlanta School of Sleep Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Zammit","sequence":"additional","affiliation":[{"name":"Clinilabs Drug Development Corporation, New York, New York"},{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gotfried","sequence":"additional","affiliation":[{"name":"Pulmonary Associates, PA, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Carter","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"},{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Black","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"},{"name":"Stanford Center for Sleep Sciences and Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Malhotra","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingman P.","family":"Strohl","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"2026030321285517900_bib1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/aje\/kws342","article-title":"Increased prevalence of sleep-disordered breathing in adults","volume":"177","author":"Peppard","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2026030321285517900_bib2","volume-title":"The International Classification of Sleep Disorders (ICSD-3)","author":"American Academy of Sleep Medicine","year":"2014","edition":"3rd ed."},{"key":"2026030321285517900_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/sleep\/27.2.194","article-title":"Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions","volume":"27","author":"Veasey","year":"2004","journal-title":"Sleep"},{"key":"2026030321285517900_bib4","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1523\/JNEUROSCI.0857-07.2007","article-title":"Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model","volume":"27","author":"Zhu","year":"2007","journal-title":"J Neurosci"},{"key":"2026030321285517900_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/rccm.2109080","article-title":"Epidemiology of obstructive sleep apnea: a population health perspective","volume":"165","author":"Young","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0272-5231(03)00014-5","article-title":"Neuropsychological impairment and quality of life in obstructive sleep apnea","volume":"24","author":"Sateia","year":"2003","journal-title":"Clin Chest Med"},{"key":"2026030321285517900_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5664\/jcsm.27662","article-title":"Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis","volume":"5","author":"Tregear","year":"2009","journal-title":"J Clin Sleep Med"},{"key":"2026030321285517900_bib8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1164\/ajrccm.164.11.2102028","article-title":"Role of snoring and daytime sleepiness in occupational accidents","volume":"164","author":"Lindberg","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/sleep\/29.3.375","article-title":"Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders","volume":"29","author":"Kushida","year":"2006","journal-title":"Sleep"},{"key":"2026030321285517900_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archinte.163.5.565","article-title":"Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis","volume":"163","author":"Patel","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026030321285517900_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.smrv.2009.02.004","article-title":"A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome","volume":"13","author":"McDaid","year":"2009","journal-title":"Sleep Med Rev"},{"key":"2026030321285517900_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.201709-1921PP","article-title":"Nasal positive airway pressure and sleep apnea: reflections on an experimental method that became a therapy","volume":"198","author":"Sullivan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jsr.12039","article-title":"Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure","volume":"22","author":"Gasa","year":"2013","journal-title":"J Sleep Res"},{"key":"2026030321285517900_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1183\/09031936.00124708","article-title":"Predictors of residual sleepiness in adequately treated obstructive sleep apnoea patients","volume":"34","author":"Koutsourelakis","year":"2009","journal-title":"Eur Respir J"},{"key":"2026030321285517900_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/sleep\/30.6.711","article-title":"Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning","volume":"30","author":"Weaver","year":"2007","journal-title":"Sleep"},{"key":"2026030321285517900_bib16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1183\/09031936.00016808","article-title":"Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study","volume":"33","author":"P\u00e9pin","year":"2009","journal-title":"Eur Respir J"},{"key":"2026030321285517900_bib17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/rccm.201307-1282ST","article-title":"An official American Thoracic Society statement: continuous positive airway pressure adherence tracking systems. The optimal monitoring strategies and outcome measures in adults","volume":"188","author":"Schwab","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40463-016-0156-0","article-title":"Trends in CPAP adherence over twenty years of data collection: a flattened curve","volume":"45","author":"Rotenberg","year":"2016","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"2026030321285517900_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/rccm.201805-1001ED","article-title":"Managing sleep apnea in those who fail continuous positive airway pressure: dealing with the invisible epidemic","volume":"198","author":"Borker","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.sleep.2013.11.781","article-title":"Prevalence of residual excessive sleepiness during effective oral appliance therapy for sleep-disordered breathing","volume":"15","author":"Verbruggen","year":"2014","journal-title":"Sleep Med"},{"key":"2026030321285517900_bib21","article-title":"Provigil (modafinil) tablets [package insert]","year":"2015"},{"key":"2026030321285517900_bib22","article-title":"Nuvigil (armodafinil) tablets [package insert]","year":"2017"},{"key":"2026030321285517900_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","article-title":"Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy","volume":"26","author":"Schwartz","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"2026030321285517900_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.clinthera.2006.05.013","article-title":"Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea\/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults","volume":"28","author":"Roth","year":"2006","journal-title":"Clin Ther"},{"key":"2026030321285517900_bib25","article-title":"Modafinil: summary of product characteristics and package leaflet","author":"European Medicines Agency (EMA)"},{"key":"2026030321285517900_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2026030321285517900_bib27","doi-asserted-by":"crossref","first-page":"A237","DOI":"10.1093\/sleepj\/zsx050.640","article-title":"A phase 3, randomized, placebo-controlled, double-blind, 12-week, multicenter study of the efficacy and safety of JZP-110 for the treatment of excessive sleepiness in patients with obstructive sleep apnea [abstract]","volume":"40","author":"Schweitzer","year":"2017","journal-title":"Sleep"},{"key":"2026030321285517900_bib28","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1016\/j.sleep.2017.11.875","article-title":"Results of a randomized, placebo-controlled, double-blind, 12-week, multicenter study of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea [abstract]","volume":"40","author":"Schweitzer","year":"2017","journal-title":"Sleep Med"},{"key":"2026030321285517900_bib29","doi-asserted-by":"crossref","first-page":"A1062","DOI":"10.1016\/j.chest.2017.08.1097","article-title":"Results of a randomized, placebo-controlled, double-blind, 12-week, multicenter study of JZP-110 for the treatment of excessive sleepiness in patients with obstructive sleep apnea [abstract]","volume":"152","author":"Strohl","year":"2017","journal-title":"Chest"},{"key":"2026030321285517900_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"2026030321285517900_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/sleep\/28.1.113","article-title":"Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test","volume":"28","author":"Littner","year":"2005","journal-title":"Sleep"},{"key":"2026030321285517900_bib32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/sleep\/20.10.844","article-title":"Daytime sleepiness and sleep habits of Australian workers","volume":"20","author":"Johns","year":"1997","journal-title":"Sleep"},{"key":"2026030321285517900_bib33","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"Guy","year":"1976"},{"key":"2026030321285517900_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/sleep\/32.7.915","article-title":"Development of the FOSQ-10: a short version of the Functional Outcomes of Sleep Questionnaire","volume":"32","author":"Chasens","year":"2009","journal-title":"Sleep"},{"key":"2026030321285517900_bib35","article-title":"Work productivity and activity impairment questionnaire: specific health problem V2.0 (WPAI:SHP)","author":"Reilly"},{"key":"2026030321285517900_bib36","volume-title":"User\u2019s manual for the SF-36v2 health survey","author":"Ware","year":"2007","edition":"2nd ed."},{"key":"2026030321285517900_bib37","article-title":"EQ-5D-5L user guide","author":"The EuroQol Group","year":"2013"},{"key":"2026030321285517900_bib38","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2026030321285517900_bib39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.5665\/sleep.5968","article-title":"Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study","volume":"39","author":"Ruoff","year":"2016","journal-title":"Sleep"},{"key":"2026030321285517900_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0013-4694(97)00010-2","article-title":"A normative study of the maintenance of wakefulness test (MWT)","volume":"103","author":"Doghramji","year":"1997","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"2026030321285517900_bib41","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","article-title":"Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy","volume":"16","author":"Bogan","year":"2015","journal-title":"Sleep Med"},{"key":"2026030321285517900_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann Neurol"},{"key":"2026030321285517900_bib43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.5664\/jcsm.5096","article-title":"Effect of wakefulness-promoting agents on sleepiness in patients with sleep apnea treated with CPAP: a meta-analysis","volume":"11","author":"Sukhal","year":"2015","journal-title":"J Clin Sleep Med"},{"key":"2026030321285517900_bib44","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinthera.2016.02.004","article-title":"Effects of modafinil and armodafinil in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials","volume":"38","author":"Kuan","year":"2016","journal-title":"Clin Ther"},{"key":"2026030321285517900_bib45","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1164\/ajrccm.164.9.2103032","article-title":"Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea","volume":"164","author":"Pack","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/sleep\/28.4.464","article-title":"Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea\/hypopnea syndrome","volume":"28","author":"Black","year":"2005","journal-title":"Sleep"},{"key":"2026030321285517900_bib47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1164\/rccm.201704-0672LE","article-title":"The Epworth Sleepiness Scale: minimum clinically important difference in obstructive sleep apnea","volume":"197","author":"Patel","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5664\/jcsm.27497","article-title":"Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults","volume":"5","author":"Epstein","year":"2009","journal-title":"J Clin Sleep Med"},{"key":"2026030321285517900_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/ajrccm.163.1.2001008","article-title":"Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study","volume":"163","author":"Shahar","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.200911-1746OC","article-title":"Obstructive sleep apnea-hypopnea and incident stroke: the Sleep Heart Health Study","volume":"182","author":"Redline","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccm.2010.02.010","article-title":"Cardiovascular consequences of sleep apnea","volume":"31","author":"Selim","year":"2010","journal-title":"Clin Chest Med"},{"key":"2026030321285517900_bib52","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1164\/rccm.201311-2012OC","article-title":"Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women","volume":"189","author":"Campos-Rodriguez","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321285517900_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.sleep.2017.03.006","article-title":"Sleep duration associated with cardiovascular conditions among adult Nevadans","volume":"34","author":"Pergola","year":"2017","journal-title":"Sleep Med"},{"key":"2026030321285517900_bib54","doi-asserted-by":"crossref","first-page":"e001454","DOI":"10.1161\/JAHA.114.001454","article-title":"Habitual sleep duration and predicted 10-year cardiovascular risk using the pooled cohort risk equations among US adults","volume":"3","author":"Ford","year":"2014","journal-title":"J Am Heart Assoc"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/11\/1421\/67116502\/ajrccm_199_11_1421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/11\/1421\/67116502\/ajrccm_199_11_1421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:29:11Z","timestamp":1772591351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/199\/11\/1421\/8498074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,6,1]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201806-1100oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,6,1]]}}}